Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12D Mutations”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07554859
What this trial is testing

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc. 90
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT07303465
What this trial is testing

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Who this might be right for
KRAS G12D MutationsPancreatic Ductal Adenocarcinoma (PDAC)
Ranok Therapeutics (Hangzhou) Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT06770452
What this trial is testing

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Who this might be right for
Metastatic Pancreatic Carcinoma
Zhejiang University 133
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385678
What this trial is testing

HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 47
Large-scale testing (Phase 3)Not Yet RecruitingNCT07656376
What this trial is testing

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

Who this might be right for
Pancreatic CancerPancreatic Carcinoma
Jiangxi Kvvit Pharmaceutical Co., Ltd. 465
Early research (Phase 1)Looking for participantsNCT07456046
What this trial is testing

D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

Who this might be right for
KRAS P.G12D
D3 Bio (Wuxi) Co., Ltd 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07784374
What this trial is testing

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Who this might be right for
Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc. 120
Large-scale testing (Phase 3)Looking for participantsNCT07668752
What this trial is testing

Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Who this might be right for
KRAS G12D MutationNSCLC (Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc. 300
Testing effectiveness (Phase 2)Looking for participantsNCT07610798
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Who this might be right for
Advance Solid TumorsColon and Rectal CancerNon - Small Cell Lung Cancer NSCLC+4 more
Shenzhen Ionova Life Sciences Co., Ltd. 178
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Early research (Phase 1)Looking for participantsNCT06227377
What this trial is testing

QTX3034 in Patients With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Quanta Therapeutics 250
Early research (Phase 1)Looking for participantsNCT05382559
What this trial is testing

ASP3082 in Adults With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 681
Testing effectiveness (Phase 2)Looking for participantsNCT07240766
What this trial is testing

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Who this might be right for
Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06385925
What this trial is testing

TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited 440
Testing effectiveness (Phase 2)Looking for participantsNCT07020221
What this trial is testing

VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more
Verastem, Inc. 295
Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Looking for participantsNCT07566052
What this trial is testing

Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc. 356
Large-scale testing (Phase 3)Looking for participantsNCT07777822
What this trial is testing

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Who this might be right for
NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more
Revolution Medicines, Inc. 430
Large-scale testing (Phase 3)Looking for participantsNCT07232875
What this trial is testing

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Who this might be right for
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Jiangsu HengRui Medicine Co., Ltd. 588
Next Page